Lundbeck, Takeda planning Japanese regulatory submission for vortioxetine

H. Lundbeck A/S (CSE:LUN) and partner Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) plan to submit a regulatory application in Japan this

Read the full 202 word article

User Sign In